Previous 10 | Next 10 |
Avenue Therapeutics, Inc. (ATXI) Investor Update Conference Call June 03, 2019 09:00 AM ET Company Participants Joe Vazzano - CFO Dr. Lucy Lu - President & CEO Dr. Neil Singla - Chief Scientific Officer of Lotus Clinical Research Conference Call Participants Jonathan As...
Thinly traded nano cap Avenue Therapeutics (NASDAQ: ATXI ) is up 16% premarket on light volume in reaction to a successful second Phase 3 clinical trial evaluating IV tramadol for the treatment of postoperative pain following abdominoplasty (tummy tuck) surgery. More news on:...
Genocea Biosciences (NASDAQ: GNCA ) +94% on positive GEN-009 data in cancer patients. More news on: Genocea Biosciences, Inc., Cypress Semiconductor Corporation, Outlook Therapeutics, Inc., Stocks on the move, Read more ...
NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that its second pivotal Phase 3 trial of IV tramad...
Avenue Therapeutics (NASDAQ: ATXI ): Q1 GAAP EPS of -$0.82 misses by $0.39 . More news on: Avenue Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first...
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Dr. Thomas G. Moore has been appointed to it...
Mustang Bio, Inc. ( MBIO ) soared last Thursday after the very successful results of its gene therapy, MB-107, for X-linked Severe Combined Immunodeficiency, or X-SCID, were published in the New England Journal of Medicine. The therapy, licensed from the St. Jude Children's Research Hospital, ...
Fortress Biotech ( FBIO ) continues to make strides since bottoming out in December. Up a hefty 134% since my last coverage on December 19, plenty of upside remains for the stock. This is because Fortress’s strong jump at the end of January had nothing at all to do with my thesis for ...
Avenue Therapeutics (NASDAQ: ATXI ): FY GAAP EPS of -$2.10. More news on: Avenue Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...